Remind to Move Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy

Remind to Move Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy: A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02645331

Enrollment

Registered

2016-01-01

Start date

2013-02-28

Completion date

2015-09-30

Last updated

2016-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiplegic Cerebral Palsy, Upper Extremity Hemiplegia

Brief summary

The aim of this study was to determine the effects of an innovative child-friendly remind-to-move treatment (RTM) treatment by comparing it with constraint-induced movement therapy (CIMT) on upper extremity outcomes in children with hemiplegic Cerebral Palsy. In an evaluator-blinded randomized controlled trial, 73 children, among of whom 20 in Manual Ability Classification System level I, 38 level II, and 15 level III, were recruited from 3 special schools and randomized to receive 75-hour RTM (n=25) and CIMT (n=24) programme over 15-weekdays, and conventional treatment (n=24). The primary outcomes were Jebsen-Taylor Hand Function Test (JTHFT) and Bruininks-Oseretsky Test of Motor Proficiency (BOTMP-II) Subtest 3 for assessing the motor efficiency at baseline, posttest, and 1- and 3-month follow-up.

Interventions

BEHAVIORALRemind-to-move

BEHAVIORALModified constraint induced movement therapy

BEHAVIORALConventional rehabilitation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

5 Years to 16 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Hemiplegic Cerebral Palsy * Aged 5 to 16 years * Ability to follow instructions * Ability to grasp and release light objects, and at least 20° wrist and 10°fingers in metacarpophalangeal joints extension from full flexion for the affected hand * Manual Activity Classification System (MACS) 19 grades I, II or III of the affected hand

Exclusion criteria

* Severe cognitive, visual, or auditory disorder * Seizure and health problems not associated with cerebral palsy * Predominant spasticity or contracture grades more than 3 of Modified Ashworth Scale 20 on wrist and finger flexors, forearm pronators and ⁄ or thumb adductors * Receiving new pharmaceutical (i.e. botulinum toxin injections) and/or surgical interventions within 6-month before study

Design outcomes

Primary

Measure	Time frame
Jebsen-Taylor Hand Function Test (JTHFT)	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)
Bruininks-Oseretsky Test of Motor Proficiency (2nd ed.) (BOTMP-II)	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)

Secondary

Measure	Time frame
Caregiver Functional Use Survey (CFUS)	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)
Ratio of movement duration on the affected hand from accelerometer	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)
Active range of motion (AROM) as measured by digital goniometer	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)
Power grip strength as measured by dynamometer	Change from Baseline at 3 weeks (plus follow up at 1 month and 3 months after training)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026